PDF factsheet

cholesterol lowering intervention in diabetes type 2 for secondary prevention, clinical trials results

aggressive cholesterol-lowering versus moderate cholesterol-lowering
Post CABG (diabetic sub group), 1999
aggressive cholesterol-lowering
moderate cholesterol-lowering
patients 1-11 years after CABGdouble blind
atorvastatin high dose versus atorvastatin
TNT (diabetic sub group), 2006
atorvastatin 80 mg daily
atorvastatin 10 mg daily
patients with stable coronary heart disease double blind
Follow-up duration: 4.9 y
fluvastatin versus placebo
LIPS (diabetic sub group), 2002
patients (aged 18-80 years) with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 135 and 270 mg/dLdouble blind
Follow-up duration: 3.9y
gemfibrozil versus placebo
VA-HIT (diabetic sub group), 1999
gemfibrozil 1200 mg per day
men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less.double blind
Follow-up duration: 5.1 y
pravastatin versus placebo
PROSPER diabetic (sub group), 2002
pravastatin 40mg daily
mena and women aged 70–82 years with a history of, or risk factors for, vascular diseasedouble blind
Follow-up duration: 3.2y mean
LIPID (diabetic sub group), 1998
pravastatin 40 mg daily
patients with a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliterdouble blind
Follow-up duration: mean 6.1y
Australia, New Zealand
CARE (diabetic sub group), 1998
men and postmenopausal women between 21 to 75 years of age, with MI between 3 and 20 months before randomization and plasma total cholesterol values <240mg/dL, LDL-C levels between 115 and 174mg/dL, and triglycerides <350mg/dL
pravastatin versus usual care
GISSI P (diabetic sub group), 2000
pravastatin 20 mg daily
usual care
recent acute myocardial infarction patients (< or = 6 months) with total blood cholesterol > or = 200 mg/dl open
Follow-up duration: median 24.3 months
pravastatin high dose versus pravastatin
PROVE IT TIMI 22 (diabetic sub group), 2006
pravastatin 80mg daily
pravastatin 40mg daily
patients hospitalized for an acute coronary syndrome within the preceding 10 daysdouble blind
Follow-up duration: 24 months mean
simvastatin versus placebo
4S (diabetic sub group), 1999
diabetic men and women aged 35 to 70 years with previous MI or active, stable angina pectoris and with serum total cholesterol level between 5.5 to 8.0 mmol/L and serum triglyceride level <=2.5 mmol/Ldouble blind
Follow-up duration: 5.4y
Denmark, Finland, Iceland, Norway, and Sweden


in first

in second